Role of Auditory Cortical Oscillations in Speech Processing and Dyslexia

Sponsor
University of Geneva, Switzerland (Other)
Overall Status
Completed
CT.gov ID
NCT04277351
Collaborator
Wyss Center for Bio and Neuroengineering (Other)
30
1
1
24
1.3

Study Details

Study Description

Brief Summary

This study aims at investigating the role of low-gamma activity in phonemic encoding and its implication in dyslexia. Indeed, a phonological deficit, i.e. a difficulty in perceiving the sounds of speech, is strongly suspected in dyslexia but has never been conclusively associated with a specific underlying mechanism.

The study employs transcranial alternating current stimulation in adults with and without dyslexia to exploit the effect of the stimulation on phonemic processing and neural activity measured with electroencephalography. In doing so, it would be possible to establishing a causal link between gamma oscillations and the phonological deficit in dyslexia.

Condition or Disease Intervention/Treatment Phase
  • Device: Transcranial alternating current stimulation
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
Single (Participant)
Masking Description:
One of three different tACS conditions is administered to all participant during three experimental days. The conditions differ in the frequency of stimulation (condition 1 and 2) and in whether the stimulation is active or faked (sham). The order of the three stimulation conditions is counterbalanced across participants, who are not aware of which tACS condition they are undergoing.
Primary Purpose:
Basic Science
Official Title:
Role of Auditory Cortical Oscillations in Speech Processing and Its Dysfunction in Dyslexia Through Transcranial Alternating Current Stimulation
Actual Study Start Date :
Sep 1, 2016
Actual Primary Completion Date :
Sep 1, 2018
Actual Study Completion Date :
Sep 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: tACS in individuals with and without dyslexia

Each participant in both the group of normo-readers and individuals with dyslexia receive all tACS stimulation conditions (fixed frequencies and sham) over different experimental days.

Device: Transcranial alternating current stimulation
Focal transcranial stimulation over auditory cortex by means of 5 electrodes delivering an electric current (max. 2mA). In addition to active stimulation, also a placebo (sham) stimulation is employed as a control condition. All subjects included in the study receive all tACS stimulation conditions.

Outcome Measures

Primary Outcome Measures

  1. Measure low-gamma neural oscillations with electroencephalography recordings [6 hour]

    Auditory-steady state responses to auditory stimuli are measured to assess specific differences between individuals with dyslexia and normo-readers, and between the different tACS stimulation conditions before, after and 1h after the 20 min. tACS stimulation. These neural correlated are estimated by considering the power of EEG signal at the frequency used to modulate the auditory stimuli.

  2. Changes in linguistic performance through a battery of behavioral tests [6 hours]

    Measurement of phonemic and syllabic processing (pseudoword repetition and spoonerism test), and reading (reading a 3 min. text, both accuracy and reading speed are considered) skills. These tests are repeated before, after and 1h after the tACS stimulation.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 18-65 years old;

  • French native speakers;

  • normally-hearing;

  • intellectual quotient (IQ) around average;

  • for the dyslexia group: previous diagnosis of dyslexia as assessed by a speech therapist.

Exclusion Criteria:
  • Presence of metal or electronic implants in the brain/skull;

  • Presence of metal or electronic device at other in other parts of the body;

  • Have experienced a seizure or a loss of consciousness or a severe head trauma;

  • Severe brain related illness ;

  • Intake of central nervous system-effective medication;

  • Pregnant and nursing women;

  • Relatives affected by epilepsy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Campus Biotech Geneva Geneva Switzerland 1202

Sponsors and Collaborators

  • University of Geneva, Switzerland
  • Wyss Center for Bio and Neuroengineering

Investigators

  • Principal Investigator: Anne-Lise Giraud, Prof., University of Geneva

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Anne-Lise Giraud, Professor, University of Geneva, Switzerland
ClinicalTrials.gov Identifier:
NCT04277351
Other Study ID Numbers:
  • PHONOSTIM
First Posted:
Feb 20, 2020
Last Update Posted:
Feb 20, 2020
Last Verified:
Feb 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 20, 2020